Abstract
Drug Delivery Technology: Assessing its potential
The time when advanced drug delivery was merely a means for profitable product
life extension has gone. Drug delivery is now a major component of the
pharmaceutical industry' s future and critical to bringing novel therapies to
market.
Indeed, without the ability to effectively deliver targeted drugs in
therapeutically significant quantities, many of the gene-based agents in
research would not be viable. Despite the importance of the sector, the
pharmaceutical industry has not always been quick to embrace the full range of
potential technologies and opportunities on offer.
With so many companies pursuing a wide range of research strategies, it is
difficult for industry and commercial executives to get a balanced and
independent overview of the competitive landscape.
That is why this major new 4-volume report, Drug Delivery Technologies:
Players, Products and Prospects to 2018, is essential reading for everyone in
the field, from niche technology specialists through to the investment
community and the pharmaceutical industry itself.
By 2018 sales of products using the novel drug delivery technology assessed in
this report could exceed US$58 billion.
This report provides a detailed insight into the current and future market for drug delivery technology and...
- Provides an overview of the marketplace, outlining current thinking on the
technologies being researched and employed;
- Appraises currently available products which utilise drug delivery
technology and assesses their future;
- Examines new product developments from major specialist drug delivery
companies, critically analysing the prospects at the product level and
forecasting sales;
- Allows ready comparison on different technologies within a company' s
portfolio;
- Provides a unique window on the sector' s product launch timetable;
- Includes detailed appendices which allow at-a-glance reviews of the
competitive landscape for both new and up and coming products.
Use this report to...
- Assess the strengths and weaknesses of competing products/technologies in
the context of specific delivery sectors and development companies;
- Identify and review licencing and collaboration partners;
- Understand the merits and applications of the main approaches being
researched;
- Quantify the commercial prospects for current and future products.
Volume I
Controlled-release Delivery
The controlled-release market was worth nearly US$21 billion globally in 2008.
The sector is dominated by the launch of oral controlled-release formulations
in key therapeutic areas such as the central nervous system, cardiovascular,
metabolic and respiratory diseases. The growth of controlled-release delivery
continues to be fuelled by line extensions helping to offset the impact of
generic erosion. We estimate there are around 60 approved controlled-release
products which will generate global sales of over US$21.5 billion in 2009,
peaking at around US$29.5 billion in 2017 as products mature and face patent
expiration leading to a decline in mature product sales to US$28.9 billion by
2018. In addition, we forecast that controlled-release products in
development from 17 key companies could generate additional sales of over
US$5.1 billion by 2018.
Impact on product lifecycles
Controlled-release technologies, possibly more than any other approved
delivery systems, have been an important tool for pharmaceutical companies to
protect their branded franchises from the ever increasing and competitive
generic market. These formulations play a critical role in establishing a
balanced portfolio of solid dosage products and may lead to enhanced efficacy
and improved patient compliance. This leads to reductions in patient costs
and extending product life-cycle management for both branded and generic
pharmaceuticals.
In the past, pharmaceutical companies have tended to develop
controlled-release formulations as immediate-release counterparts near patent
expiration. This trend is reversing and companies are developing
controlled-release formulations earlier in the product life-cycle and often
launching multiple formulations (immediate release, controlled release/
modified release, and delayed release) in parallel to expand the potential
addressable patient population and gain a significant share of competitive
market places.
This report answers key questions...
- Who will have launched novel products by 2018 and what technologies could
they be using?
- Can market leaders such as ALZA and Elan maintain their status in
controlled release in the face of growing competition?
- What obstacles must companies overcome to achieve full market potential?
- What strategies are proving most productive and for which companies?
- What will the product/company landscape look like in 2018?
Volume II
Nano-enabled Delivery
The true value of nanotechnology lies in its potential to improve the
solubility and enhance the efficiency of product delivery. It has been
successfully applied to the commercialisation of more than 30 drugs.
Regulators have published numerous white papers on the topic and established
Task Forces to monitor the progress and application of this technology
although there are presently no regulations specific to nanomedicine or
nano-enabled medical devices.
As the field of nanotechnology gains momentum and nano-enabled platforms
emerge to address the industry' s need for therapeutic, bioavailable and less
toxic products, this market is expected to grow significantly over the next
decade. Proof of concept data with novel compounds is accumulating and new
formulations of old chemotherapeutic drugs offer the promise to revolutionise
cancer therapies.
The potential of future applications:
- Tissue specific delivery - targeting the delivery of small and macro
molecules across biological membranes such as the blood brain barrier for CNS
drugs;
- Gene and vaccine delivery - non-viral delivery of genetic materials in
nanohydrogels and nanocarriers with a high degree of efficiency and expression;
- Controlled-release devices - design of new nanoporous, bioerodible
membranes;
- Increased biocompatibility - design of artificial surfaces engineering
for medical and dental implants to by-pass unwanted inflammatory response;
- Improved drug bioavailability and solubility - through the engineering of
drugs and reagents by nanostructuring;
- Applied diagnosis, etiology, prognosis and therapy (ADEPT) technology for
the safe targeted delivery of toxic therapeutic drugs.
By 2018, the market could exceed US$13 billion
By 2018 the established nanotechnology product market will be US$10.2 billion.
The market will mature as the number of marketed nano-enabled products
doubles and second generation nanomedicines begin to emerge. These agents
will address areas of high unmet clinical need and result in the formulation
of approved and novel drugs which are safer, less toxic and more efficacious
than first generation products.
By 2018 these second generation nanomedicines could generate sales of nearly
US$2.9 billion and establish nanotechnology as an important tool in the
industry' s delivery armoury. A range of proprietary delivery platforms will
utilise CaP technologies, FluidCrystals, micelles and polymeric nanoparticles
to target a number of therapy areas such as CNS disorders, oncology and
infectious diseases.
Volume III
Nucleic Acid Delivery
The nucleic acid delivery market is maturing with over 1,450 clinical trials
underway worldwide. The majority of these are in early clinical development
(approximately 60%) with just over 3% in Phase III trials. Our analysis
indicates that up to 35 novel nucleic acid products could reach the market
within our forecasting period (2008-2018). However the harsh economic
environment may force companies to place promising drugs on hold as they focus
on lead projects rather than multiple programmes. To date, only a handful of
nucleic acid-based products have been approved for human prescription and
these products rely on delivery technologies in one shape or form. We
estimate the nucleic acid market was worth just over US$80 million globally in
2008.
By 2018 we anticipate the nucleic acid technology market will have matured as
many of the late-stage clinical programmes come to fruition and drug delivery
companies continue to overcome issues surrounding its safety and efficiency.
The development of nucleic acid delivery systems will help to improve
specificity whilst the development of novel polymers and lipopolymer complexes
will help to carry larger DNA payloads in order to target cells and make
multigene targeting a reality. We forecast that nucleic acid products in
development from 11 key companies could generate additional sales of nearly
US$2.3 billion by 2018. These products utilise a range of delivery platforms
including viral to non-viral delivery systems, and cover gene therapies, gene
agents and DNA vaccines for a variety of targets including cancer,
cardiovascular and infectious diseases.
Catalysts for change
- Improvements in our understanding into the underlying genetic causes of
disease as well as the uptake of new mechanisms of modulating DNA such as RNA
interference which will help to fuel market growth.
- The development of a new generation of DNA vaccines that will provoke
strong immunogenic responses and will help to determine whether this has been
a sound investment for the pharma industry.
- Launch of the first siRNA-based therapeutics (although progress has been
dampened following the recent termination of Opko Health' s leading eye
treatment at the Phase III development stage). We anticipate companies will
pursue other conditions such as infectious diseases and cancer where robust
preclinical studies have already been performed and where drug delivery
platforms have been adopted rather than the use of naked siRNAs.
Which companies and products will dominate?
This volume will tell you!
Volume IV
Targeted Delivery
By 2018, over 30 new products will be launched resulting in a global market for advanced targeted delivery products worth over US$8.5 billion.
Despite considerable advances in drug delivery technologies, there continues
to be a high unmet clinical need for safer and better-tolerated drugs.
Sub-optimal compliance and failure to persist with drug treatments are
important determinants of therapeutic non-response and are of significant cost
to healthcare providers. Advanced targeted drug delivery technologies will
help to overcome some of these issues by improving pharmacokinetics,
increasing tolerability and reducing dose-limiting off-target effects.
The need for targeted delivery platforms is increasing as patients and drug
regulators seek to meet these challenges.
Current and future applications
Whilst the majority of targeted delivery systems under evaluation incorporate
passive carrier systems, there will be a shift towards the use of actively
targeted carriers to increase the therapeutic index of existing and new
products. There are significant opportunities for future commercial
developments within the pharmaceutical industry.
These include:
- Cost-effective production of antibodies and antibody fragments for drug
targeting;
- Development of new polymers and biopolymers that may be utilised in the
safe and efficient targeted delivery of drugs and pro-drugs into host cells;
- Development and selective targeting of macromolecules to improve
intracellular uptake and tissue specificity;
- Development of inactive pro-drugs for tissue specific release;
- Extended product life-cycles through the development of targeted
formulations;
- Identification of new targeting ligands to improve the targeted delivery
of small molecules and macromolecules;
- Utilisation of multiple targeting ligands to address the needs of patient
sub-types;
- Combined technology platforms to develop targeted therapeutics and
diagnostics in a single molecule.
A new generation of targeted delivery systems is under development to meet
these needs which should provide greater control over the selective targeting
of tissue, either with active moieties or inactive moieties which may be
activated within the tissue by biological (enzymes), chemical (pH) or physical
means (light, ultrasound) in order to release the active agent. The multitude
of delivery platforms will lend themselves to the delivery of both small
molecules and macromolecules and to a variety of target sites and delivery
routes.
Unique company & technology evaluation
It is vital that management information is reliable, current and insightful.
Today, product and company assessment must be seen in a wider competitive and
market environment.
In this report we present a précis on each of the leading delivery
specialists and potential new delivery platforms and have identified their key
attributes, based on a number of criteria including:
- Proprietary delivery technology
- Applications of the delivery technology within the pharmaceutical industry
- Management/technical expertise of the delivery specialist
- Competition within the delivery technology sector
- Products in development/approved utilising the delivery technology
We have established a competitor ratio analysis based on each of the criteria
mentioned above. Each criterion attracts an award of up to 10 points, with a
maximum score of 50, thus enabling the establishment of an Espicom
“ranking table” in each segment of the market, dependent on their
relative attributes.
Multi-point evaluation and scoring assessment
Pharma drugs that utilise drug delivery systems have been evaluated based on a
number of parameters, including:
The technology
Comparison of delivery platforms within each area including: activated,
degradation or diffusion for controlled-release systems; nano-engineered
(nanocrystals, nanoparticle, nanosuspension) or nanocarriers (carbon/ceramic,
dendrimer, liposome, micelle, polymeric nanoparticles) for nano-enabled
delivery; viral or non-viral platforms for nucleic acid delivery and active or
passive platforms for targeted delivery systems
The application of the technology within a number of therapy areas
Route of delivery (oral, parenteral, transdermal, implantable), delivery of
small molecules/macromolecules and vaccines, additional features such as
bioerodible materials etc
The current status of the technology in clinical development or following
approval
Number of approved and marketed products, clinical or preclinical development
candidates, single or multiple products.
Competition within the technology arena
Alternative drug delivery systems to technologies under evaluation, advantages
and disadvantages over competitors.
The drug delivery specialist' s expertise
Number of drug delivery systems in development, strategic alliances, financial
position, marketing presence.
The product portfolio
Drug delivery systems under evaluation, products in development,
commercialisation/development partnerships.
Potential drug sales
Based on key events such as market, competition, patent expiry, time of entry
into the market.
Table of Contents
REPORT OVERVIEW
- Controlled-Release Delivery Technologies
- Nano-enabled Delivery Technologies
- Nucleic Acid Delivery Technologies
- Targeted Delivery Technologies
- Competitor Ratio Analysis Summary
DRUG DELIVERY TECHNOLOGIES: CONTROLLED-RELEASE
- EXECUTIVE SUMMARY
- INTRODUCTION
- Overview of controlled-release delivery: past, present & future
- Leading controlled-release technology platforms & characteristics
- Controlled delivery profiles
- Controlled-release delivery: motivators & resistors
- Motivators
- Controlled-Release technology motivators
- Resistors
- Controlled-Release technology resistors
- Controlled-release delivery: impact on product lifecycles
- Impact of reformulation on product life-cycle
- CONTROLLE D-RELE ASE DELIVE RY
- Types of controlled-release delivery used by pharma industry
- Activated controlled-release delivery
- Activated controlled-release delivery - ALZA' s OROS systems
- Degradation controlled-release delivery
- Degradation controlled-release delivery - SkyePharma' s GEOMATRIX
- Diffusion controlled-release delivery
- Monolithic diffusion controlled-release delivery - LaboPharm' s Contramid
- Reservoir diffusion controlled-release delivery - Impax' CMDS
- Combined controlled-release delivery - Flamel' s Micropump
- Advantages and disadvantages of controlled-release platforms
- Current therapeutic application of controlled-release in drug delivery
- Leading brands that utilise controlled-release delivery
- Leading controlled-release approved drugs
- Future commercial applications & opportunities
- STRATEGIE S OF DRUG DELIVE RY COMPANIE S
- Leading controlled-release drug delivery companies
- Leading controlled-release drug delivery companies
- Partnerships & acquisitions
- Strategic developmental & commercialisation partnerships
- Merger & acquisitions
- Recent partnerships & acquisitions in the controlled-release field
- Intellectual Property
- Controlled-Release patents
- THE CONTROLLED - RELEASE MARKET
- Now 2009
- Approved controlled-release product sales
- Future 2018
- Global controlled-release product sales
- Novel controlled-release product sales
- COMPETITOR ANALYSIS
- Movers & Shakers: Cutting edge or losing their grip
- Movers & shakers in controlled-release drug delivery systems
- COMPANY PROFILES
- AlphaRx Corporation
- Proprietary delivery technology
- Applications in the pharma industry
- Management/technical expertise
- Competition within the delivery technology sector
- Products in development/approved utilising the delivery technology
- AlphaRx' product pipeline
- Sales forecasts of products utilising the delivery technology
- AlphaRx' drug delivery sales
- Competitor Ratio Analysis
- ALZA Corporation
- Proprietary delivery technology
- Applications in the pharma industry
- Management/technical expertise
- Competition within the delivery technology sector
- Products in development/approved utilising the delivery technology
- ALZA' s product pipeline
- Sales forecasts of products utilising the delivery technology
- ALZA' s drug delivery sales
- Competitor Ratio Analysis
- Antares Pharma, Inc.
- Proprietary delivery technology
- Applications in the pharma industry
- Management/technical expertise
- Competition within the delivery technology sector
- Products in development/approved utilising the delivery technology
- Antares' product pipeline
- Sales forecasts of products utilising the delivery technology
- Antares' drug delivery sales
- Competitor Ratio Analysis
- Biovail Corporation
- Proprietary delivery technology
- Applications in the pharma industry
- Management/technical expertise
- Competition within the delivery technology sector
- Products in development/approved utilising the delivery technology
- Biovail' s product pipeline
- Sales forecasts of products utilising the delivery technology
- Biovail' s drug delivery sales
- Competitor Ratio Analysis
- Camurus AB
- Proprietary delivery technology
- Camurus' FluidCrystal CR technology
- Applications in the pharma industry
- Management/technical expertise
- Competition within the delivery technology sector
- Products in development/approved utilising the delivery technology
- Camurus AB' s product pipeline
- Sales forecasts of products utilising the delivery technology
- Camurus AB' s drug delivery sales
- Competitor Ratio Analysis
- Cerulean Pharma Inc.
- Proprietary delivery technology
- Applications in the pharma industry
- Management/technical expertise
- Competition within the delivery technology sector
- Products in development/approved utilising the delivery technology
- Cerulean' s product pipeline
- Sales forecasts of products utilising the delivery technology
- Competitor Ratio Analysis
- Cipher Pharmaceuticals, Inc.
- Proprietary delivery technology
- Applications in the pharma industry
- Management/technical expertise
- Competition within the delivery technology sector
- Products in development/approved utilising the delivery technology
- Cipher' s product pipeline
- Sales forecasts of products utilising the delivery technology
- Cipher' s drug delivery sales
- Competitor Ratio Analysis
- Debiopharm Group
- Proprietary delivery technology
- Applications in the pharma industry
- Management/technical expertise
- Competition within the delivery technology sector
- Products in development/approved utilising the delivery technology
- Debiopharm' s product pipeline
- Sales forecasts of products utilising the delivery technology
- DebioPharm' s drug delivery sales
- Competitor Ratio Analysis
- DelSite Biotechnologies, Inc.
- Proprietary delivery technology
- Applications in the pharma industry
- Management/technical expertise
- Competition within the delivery technology sector
- Products in development/approved utilising the delivery technology
- DelSite' s product pipeline
- Sales forecasts of products utilising the delivery technology
- Competitor Ratio Analysis
- Depomed, Inc.
- Proprietary delivery technology
- Applications in the pharma industry
- Management/technical expertise
- Competition within the delivery technology sector
- Products in development/approved utilising the delivery technology
- Depomed' s product pipeline
- Sales forecasts of products utilising the delivery technology
- Depomed' s product sales
- Competitor Ratio Analysis
- Durect Corporation
- Proprietary delivery technology
- Applications in the pharma industry
- Management/technical expertise
- Competition within the delivery technology sector
- Products in development/approved utilising the delivery technology
- Durect' s product pipeline
- Sales forecasts of products utilising the delivery technology
- Durect' s product sales
- Competitor Ratio Analysis
- Elan Corporation
- Proprietary delivery technology
- Applications in the pharma industry
- Management/technical expertise
- Competition within the delivery technology sector
- Products in development/approved utilising the delivery technology
- Elan' s product pipeline
- Sales forecasts of products utilising the delivery technology
- Elan' s drug delivery sales
- Competitor Ratio Analysis
- Elite Pharmaceuticals, Inc
- Proprietary delivery technology
- Applications in the pharma industry
- Management/technical expertise
- Competition within the delivery technology sector
- Elite' s product pipeline
- Sales forecasts of products utilising the delivery technology
- Elite' s product sales
- Competitor Ratio Analysis
- Endo Pharmaceuticals, Inc.
- Proprietary delivery technology
- Applications in the pharma industry
- Management/technical expertise
- Competition within the delivery technology sector
- Products in development/approved utilising the delivery technology
- Endo' s product pipeline
- Sales forecasts of products utilising the delivery technology
- Endo' s product sales
- Competitor Ratio Analysis
- Ethypharm SA
- Proprietary delivery technology
- Applications in the pharma industry
- Management/technical expertise
- Competition within the delivery technology sector
- Products in development/approved utilising the delivery technology
- Ethypharm' s product pipeline
- Sales forecasts of products utilising the delivery technology
- Ethypharm' s product sales
- Competitor Ratio Analysis
- Eurand
- Proprietary delivery technology
- Applications in the pharma industry
- Management/technical expertise
- Competition within the delivery technology sector
- Products in development/approved utilising the delivery technology
- Eurand' s product pipeline
- Sales forecasts of products utilising the delivery technology
- Eurand' s product sales
- Competitor Ratio Analysis
- Flamel Technologies, Inc.
- Proprietary delivery technology
- Flamel' s Medusa technology
- Flamel' s Micropump technology
- Applications in the pharma industry
- Management/technical expertise
- Competition within the delivery technology sector
- Products in development/approved utilising the delivery technology
- Flamel' s product pipeline
- Sales forecasts of products utilising the delivery technology
- Flamel' s product sales
- Competitor Ratio Analysis
- Glycologic, Ltd.
- Proprietary delivery technology
- Applications in the pharma industry
- Management/technical expertise
- Competition within the delivery technology sector
- Products in development/approved utilising the delivery technology
- Glycologic' s product pipeline
- Sales forecasts of products utilising the delivery technology
- Competitor Ratio Analysis
- KV Pharmaceuticals, Inc.
- Proprietary delivery technology
- Applications in the pharma industry
- Management/technical expertise
- Competition within the delivery technology sector
- Products in development/approved utilising the delivery technology
- KV' s product pipeline
- Sales forecasts of products utilising the delivery technology
- Competitor Ratio Analysis
- Labopharm, Inc.
- Proprietary delivery technology
- Applications in the pharma industry
- Management/technical expertise
- Competition within the delivery technology sector
- Products in development/approved utilising the delivery technology
- Labopharm' s product pipeline
- Sales forecasts of products utilising the delivery technology
- Labopharm' s product sales
- Competitor Ratio Analysis
- Lavipharm SA
- Proprietary delivery technology
- Applications in the pharma industry
- Management/technical expertise
- Competition within the delivery technology sector
- Products in development/approved utilising the delivery technology
- Lavipharm' s product pipeline
- Sales forecasts of products utilising the delivery technology
- Competitor Ratio Analysis
- Nano Interface Technology
- Proprietary delivery technology
- Applications in the pharma industry
- Management/technical expertise
- Competition within the delivery technology sector
- Products in development/approved utilising the delivery technology
- NITI' s product pipeline
- Sales forecasts of products utilising the delivery technology
- Competitor Ratio Analysis
- OctoPlus N.V.
- Proprietary delivery technology
- Applications in the pharma industry
- Management/technical expertise
- Competition within the delivery technology sector
- Products in development/approved utilising the delivery technology
- OctoPlus' product pipeline
- Sales forecasts of products utilising the delivery technology
- OctoPlus' product sales
- Competitor Ratio Analysis
- Penwest Pharmaceuticals
- Proprietary delivery technology
- Applications in the pharma industry
- Management/technical expertise
- Competition within the delivery technology sector
- Products in development/approved utilising the delivery technology
- Penwest' s product pipeline
- Sales forecasts of products utilising the delivery technology
- Penwest' s product sales
- Competitor Ratio Analysis
- SCOLR Pharma, Inc.
- Proprietary delivery technology
- Applications in the pharma industry
- Management/technical expertise
- Competition within the delivery technology sector
- Products in development/approved utilising the delivery technology
- SCOLR' s product pipeline
- Sales forecasts of products utilising the delivery technology
- SCOLR' s drug delivery sales
- Competitor Ratio Analysis
- Shire, Plc
- Proprietary delivery technology
- Applications in the pharma industry
- Management/technical expertise
- Competition within the delivery technology sector
- Products in development/approved utilising the delivery technology
- Shire' s product pipeline
- Sales forecasts of products utilising the delivery technology
- Shire' s leading drug delivery product sales
- Competitor Ratio Analysis
- Skinvisible, Inc.
- Proprietary delivery technology
- Applications in the pharma industry
- Management/technical expertise
- Competition within the delivery technology sector
- Products in development/approved utilising the delivery technology
- Skinvisible' s product pipeline
- Sales forecasts of products utilising the delivery technology
- Competitor Ratio Analysis
- SkyePharma
- Proprietary delivery technology
- Applications in the pharma industry
- Management/technical expertise
- Competition within the delivery technology sector
- Products in development/approved utilising the delivery technology
- SkyePharma' s product pipeline
- Sales forecasts of products utilising the delivery technology
- SkyePharma' s product sales
- Competitor Ratio Analysis
- Spherics
- Proprietary delivery technology
- Applications in the pharma industry
- Management/technical expertise
- Competition within the delivery technology sector
- Products in development/approved utilising the delivery technology
- Spheric' s product pipeline
- Sales forecasts of products utilising the delivery technology
- Spheric' s product sales
- Competitor Ratio Analysis
- Watson Pharmaceuticals
- Proprietary delivery technology
- Applications in the pharma industry
- Management/technical expertise
- Competition within the delivery technology sector
- Products in development/approved utilising the delivery technology
- Watson' s product pipeline
- Sales forecasts of products utilising the delivery technology
- Watson' s drug delivery sales
- Competitor Ratio Analysis
- APPENDIX 1
- Global controlled-release approved drugs sales 2008-2018 (US$million)
- APPENDIX 2
- Global controlled-release developmental drugs sales 2008-2018 (US$million)
- APPENDIX 3
- Competitor Ratio Analysis Criteria
- Key Controlled-release delivery companies by 2015
- BIBLIOGRAPHY
- GLOSSARY
- ACRONYMS
- ENDNOTES
DRUG DELIVERY TECHNOLOGIES: NANOTECHNOLOGY
- EXECUTIVE SUMMARY
- INTRODUCTION
- Overview of nanotechnology: past, present & future
- Multifunctional nanotechnology platform
- Nanotechnology: motivators & resistors
- Motivators
- Nanotechnology motivators
- Resistors
- Nanomedicines, formulations and product regeneration
- Failure rates at each stage of clinical drug development
- NANOTECHNOLOGY IN DRUG DELIVERY
- Core nanotechnology used by the pharma industry
- Nano-engineered drugs
- Nano-carriers
- Dendrimer structure
- Liposome structure
- Micelle structure
- Polymeric nanoparticle structure - Abraxane
- Current therapeutic applications of nanotechnology in drug delivery
- Leading brands that utilise nanotechnology delivery
- Nanotechnology-enabled approved drugs
- Future commercial applications & opportunities
- STRATEGIES OF DRUG DELIVERY COMPANIES
- Leading nanotechnology drug delivery companies
- Leading nanotechnology-enabled drug delivery companies
- Partnerships & acquisitions
- Strategic development & commercialisation partnerships and joint
ventures
- Mergers, acquisitions, start ups & spin offs
- Recent partnerships & acquisitions in the nanotechnology field
- Intellectual Property
- THE NANOTECHNOLOGY MARKET
- Now 2009
- Leading approved nano-enabled product sales
- Leading companies developing nano-enabled product sales
- Future 2018
- Novel nano-enabled product sales
- Global nano-enabled product sales
- COMPETITOR ANALYSIS
- Movers & Shakers: Cutting edge or losing their grip
- Movers & shakers in nanotechnology drug delivery systems
- COMPANY PROFILES
- Abraxis Bioscience
- Proprietary delivery technology
- Abraxis Protosphere - nab technology
- Applications in the pharma industry
- Management/technical expertise
- Competition within the delivery technology sector
- Products in development/approved utilising the delivery technology
- Abraxis' product pipeline
- Sales forecasts of products utilising the delivery technology
- Abraxis' sales forecasts
- Competitor Ratio Analysis
- Access Pharmaceuticals
- Proprietary delivery technology
- ProLindac nanoparticulate prodrug
- Cobalamin coated nanoparticulates
- Applications in the pharma industry
- Management/technical expertise
- Competition within the delivery technology sector
- Products in development/approved utilising the delivery technology
- Access Pharmaceuticals product pipeline
- Sales forecasts of products utilising the delivery technology
- Access' sales forecasts
- Competitor Ratio Analysis
- AlphaRx Corporation
- Proprietary delivery technology
- Nanoparticle targeted delivery & uptake
- Applications in the pharma industry
- Management/technical expertise
- Competition within the delivery technology sector
- Products in development/approved utilising the delivery technology
- AlphaRx' product pipeline
- Sales forecasts of products utilising the delivery technology
- AlphaRx' pharmaceuticals sales
- Competitor Ratio Analysis
- ALZA Corporation
- Proprietary delivery technology
- Applications in the pharma industry
- Management/technical expertise
- Competition within the delivery technology sector
- Products in development/approved utilising the delivery technology
- Sales forecasts of products utilising the delivery technology
- ALZA' s drug delivery sales
- Competitor Ratio Analysis
- Aphios Corporation
- Proprietary delivery technology
- Applications in the pharma industry
- Management/technical expertise
- Competition within the delivery technology sector
- Products in development/approved utilising the delivery technology
- Aphios' product pipeline
- Sales forecasts of products utilising the delivery technology
- Competitor Ratio Analysis
- APR Applied Pharma Research
- Proprietary delivery technology
- Applications in the pharma industry
- Management/technical expertise
- Competition within the delivery technology sector
- Products in development/approved utilising the delivery technology
- APR' s product pipeline
- Sales forecasts of products utilising the delivery technology
- Competitor Ratio Analysis
- BioSante Pharmaceuticals
- Proprietary delivery technology
- Applications in the pharma industry
- Management/technical expertise
- Competition within the delivery technology sector
- Products in development/approved utilising the delivery technology
- BioSante' s CaP product pipeline
- Sales forecasts of products utilising the delivery technology
- BioSante' s drug delivery sales
- Competitor Ratio Analysis
- Calando Pharmaceuticals
- Proprietary delivery technology
- Schematic of cyclodextrin polymeric nanoparticles
- Applications in the pharma industry
- Management/technical expertise
- Competition within the delivery technology sector
- Products in development/approved utilising the delivery technology
- Calando' s product pipeline
- Sales forecasts of products utilising the delivery technology
- Calando' s sales forecasts
- Competitor Ratio Analysis
- Camurus AB
- Proprietary delivery technology
- Applications in the pharma industry
- Management/technical expertise
- Competition within the delivery technology sector
- Products in development/approved utilising the delivery technology
- Camurus AB' s product pipeline
- Sales forecasts of products utilising the delivery technology
- Camurus AB' s drug delivery sales
- Competitor Ratio Analysis
- Cerulean Pharma Inc.
- Proprietary delivery technology
- Applications in the pharma industry
- Management/technical expertise
- Competition within the delivery technology sector
- Products in development/approved utilising the delivery technology
- Cerulean' s product pipeline
- Sales forecasts of products utilising the delivery technology
- Competitor Ratio Analysis
- CytImmune Sciences Inc.
- Proprietary delivery technology
- CytImmune' s Colloidal Gold Nanoparticle Delivery
- Applications in the pharma industry
- Management/technical expertise
- Competition within the delivery technology sector
- Products in development/approved utilising the delivery technology
- CytImmune' s' product pipeline
- Sales forecasts of products utilising the delivery technology
- CytImmune' s sales forecasts
- Competitor Ratio Analysis
- Elan Corporation
- Proprietary delivery technology
- Applications in the pharma industry
- Management/technical expertise
- Competition within the delivery technology sector
- Products in development/approved utilising the delivery technology
- Elan' s NanoCrystal product portfolio
- Sales forecasts of products utilising the delivery technology
- Elan' s drug delivery sales
- Competitor Ratio Analysis
- Enzon Pharmaceuticals, Inc.
- Proprietary delivery technology
- Applications in the pharma industry
- Management/technical expertise
- Competition within the delivery technology sector
- Products in development/approved utilising the delivery technology
- Enzon' s product pipeline
- Sales forecasts of products utilising the delivery technology
- Enzon' s targeted product sales
- Competitor Ratio Analysis
- Gilead Sciences
- Proprietary delivery technology
- Applications in the pharma industry
- Management/technical expertise
- Competition within the delivery technology sector
- Products in development/approved utilising the delivery technology
- Gilead Sciences' product pipeline
- Sales forecasts of products utilising the delivery technology
- Gilead Sciences' drug delivery sales
- Competitor Ratio Analysis
- Introgen Therapeutics
- Proprietary delivery technology
- Applications in the pharma industry
- Management/technical expertise
- Competition within the delivery technology sector
- Products in development/approved utilising the delivery technology
- Introgen' s product pipeline
- Sales forecasts of products utilising the delivery technology
- Introgen' s sales forecasts
- Competitor Ratio Analysis
- Mersana Therapeutics
- Proprietary delivery technology
- Applications in the pharma industry
- Management/technical expertise
- Competition within the delivery technology sector
- Products in development/approved utilising the delivery technology
- Mersana' s product pipeline
- Sales forecasts of products utilising the delivery technology
- Mersana' s sales forecasts
- Competitor Ratio Analysis
- Nano Interface Technology
- Proprietary delivery technology
- Applications in the pharma industry
- Management/technical expertise
- Competition within the delivery technology sector
- Products in development/approved utilising the delivery technology
- NITI' s product pipeline
- Sales forecasts of products utilising the delivery technology
- Competitor Ratio Analysis
- Nano S Biotechnology GmbH
- Proprietary delivery technology
- S-Layer Technology Platform
- Applications in the pharma industry
- Management/technical expertise
- Competition within the delivery technology sector
- Products in development/approved utilising the delivery technology
- Nano S' product pipeline
- Sales forecasts of products utilising the delivery technology
- Competitor Ratio Analysis
- NanoBio Corporation
- Proprietary delivery technology
- Applications in the pharma industry
- Management/technical expertise
- Competition within the delivery technology sector
- Products in development/approved utilising the delivery technology
- NanoBio' s product pipeline
- Sales forecasts of products utilising the delivery technology
- NanoBio' s drug delivery sales
- Competitor Ratio Analysis
- NanoBioMagnetics
- Proprietary delivery technology
- Applications in the pharma industry
- Management/technical expertise
- Competition within the delivery technology sector
- Products in development/approved utilising the delivery technology
- NanoBioMagnetics' product pipeline
- Sales forecasts of products utilising the delivery technology
- Competitor Ratio Analysis
- Nanobiotix
- Proprietary delivery technology
- Applications in the pharma industry
- Management/technical expertise
- Competition within the delivery technology sector
- Products in development/approved utilising the delivery technology
- Nanobiotix' product pipeline
- Sales forecasts of products utilising the delivery technology
- Competitor Ratio Analysis
- NanoCarrier
- Proprietary delivery technology
- Micellar Nanoparticles
- Applications in the pharma industry
- Management/technical expertise
- Competition within the delivery technology sector
- Products in development/approved utilising the delivery technology
- NanoCarrier' s product pipeline
- Sales forecasts of products utilising the delivery technology
- NanoCarrier' s drug delivery sales
- Competitor Ratio Analysis
- Nanotechnology Victoria, Ltd.
- Proprietary delivery technology
- Applications in the pharma industry
- Management/technical expertise
- Competition within the delivery technology sector
- Products in development/approved utilising the delivery technology
- NanoVic' s product pipeline
- Sales forecasts of products utilising the delivery technology
- Competitor Ratio Analysis
- NanoMaterials Technology
- Proprietary delivery technology
- High Gravity Controlled Precipitation (HCGP) of nanomaterials
- Applications in the pharma industry
- Management/technical expertise
- Competition within the delivery technology sector
- Products in development/approved utilising the delivery technology
- NanoMaterial' s product pipeline
- Sales forecasts of products utilising the delivery technology
- Competitor Ratio Analysis
- Nanotherapeutics
- Proprietary delivery technology
- Applications in the pharma industry
- Management/technical expertise
- Competition within the delivery technology sector
- Products in development/approved utilising the delivery technology
- Nanotherapeutics' product pipeline
- Sales forecasts of products utilising the delivery technology
- Nanotherapeutics' drug delivery sales
- Competitor Ratio Analysis
- Novavax
- Proprietary delivery technology
- Applications in the pharma industry
- Management/technical expertise
- Competition within the delivery technology sector
- Products in development/approved utilising the delivery technology
- Novavax' s product pipeline
- Sales forecasts of products utilising the delivery technology
- Novavax' s drug delivery sales
- Competitor Ratio Analysis
- SkyePharma
- Proprietary delivery technology
- Applications in the pharma industry
- Management/technical expertise
- Competition within the delivery technology sector
- Products in development/approved utilising the delivery technology
- SkyePharma' s product pipeline
- Sales forecasts of products utilising the delivery technology
- SkyePharma' s product sales
- Competitor Ratio Analysis
- Spherics
- Proprietary delivery technology
- Applications in the pharma industry
- Management/technical expertise
- Competition within the delivery technology sector
- Products in development/approved utilising the delivery technology
- Spheric' s product pipeline
- Sales forecasts of products utilising the delivery technology
- Competitor Ratio Analysis
- Starpharma
- Proprietary delivery technology
- Dendrimer nanotechnology
- Applications in the pharma industry
- Management/technical expertise
- Competition within the delivery technology sector
- Products in development/approved utilising the delivery technology
- Starpharma' s product pipeline
- Sales forecasts of products utilising the delivery technology
- Starpharma' s product sales
- Competitor Ratio Analysis
- APPENDIX 1
- Global nanotechnology approved drugs sales 2008-2018
- APPENDIX 2
- Global nanotechnology developmental drugs sales 2008-2018
- APPENDIX 3
- Competitor Ratio Analysis Criteria
- Key nanotechnology delivery companies by 2018
- GLOSSARY
- ACRONYMS
- BIBLIOGRAPHY
- ENDNOTES
DRUG DELIVERY TECHNOLOGIES: NUCLEIC ACID
- EXECUTIVE SUMMARY
- INTRODUCTION
- Overview of delivery technologies for genetic material: past, present &
future
- Leading technology platforms for the delivery of genetic material
- Nucleic acid delivery: motivators & resistors
- Nucleic acid technology motivators
- Motivators
- Nucleic acid technology resistors
- Resistors
- ADVANCED NUCLEIC ACID DELIVERY TECHNOLOGIES
- Types of nucleic acid-based products under development by the pharma
industry
- Viral vector delivery of nucleic acids
- Schematic of gene therapy utilising HVJ envelope - virosome
- Bacterial vector delivery of nucleic acids
- Non-viral vector delivery of nucleic acids
- Chemical Technologies
- Stable nucleic acid-lipid particles
- Targeted nanoparticles
- Physical Technologies
- Schematic of Zosano Pharma' s Patch Technology
- Advantages and disadvantages of nucleic acid platforms
- Current therapeutic applications for the viral and non-viral delivery of
nucleic acids
- Leading nucleic acid based products in development
- Nucleic acid-based approved/filed drugs
- Selection of gene therapies in clinical development
- Selection of RNA therapeutics in clinical development
- Selection of DNA vaccines in clinical development
- Future commercial applications & opportunities
- STRATEGIES OF DRUG DELIVERY COMPANIES
- Leading nucleic acid drug delivery companies
- Leading nucleic acid drug delivery specialists
- Partnerships & acquisitions
- Strategic developmental & commercialisation partnerships
- Mergers, acquisitions & joint ventures
- Recent partnerships & acquisitions in the nucleic acid field
- Intellectual Property
- THE VIRAL AND NON-VIRAL VECTOR DELIVERY MARKET
- Now 2009
- Approved nucleic acid product sales
- Future 2018
- Novel nucleic acid product sales
- Global controlled release product sales
- COMPETITOR ANALYSIS
- Movers & Shakers: Cutting edge or losing their grip
- Movers & shakers in nucleic acid drug delivery systems
- COMPANY PROFILES
- Alnylam Pharmaceuticals
- Proprietary delivery technology
- Applications in the pharma industry
- Management/technical expertise
- Competition within the delivery technology sector
- Products in development/approved utilising the delivery technology
- Alnylam' s product pipeline
- Sales forecasts of products utilising the delivery technology
- Alnylam' s sales forecasts
- Competitor Ratio Analysis
- AlphaVax, Inc.
- Proprietary delivery technology
- The alphavaccine platform system
- Applications in the pharma industry
- Management/technical expertise
- Competition within the delivery technology sector
- Products in development/approved utilising the delivery technology
- AlphaVax' product pipeline
- Sales forecasts of products utilising the delivery technology
- AlphaVax' sales forecasts
- Competitor Ratio Analysis
- Altea Therapeutics, Inc.
- Proprietary delivery technology
- Altea Therapeutics' Passport Patch
- Applications in the pharma industry
- Management/technical expertise
- Competition within the delivery technology sector
- Products in development/approved utilising the delivery technology
- Altea Therapeutics' product pipeline
- Sales forecasts of products utilising the delivery technology
- Competitor Ratio Analysis
- AP Pharma, Inc.
- Proprietary delivery technology
- Applications in the pharma industry
- Management/technical expertise
- Competition within the delivery technology sector
- Products in development/approved utilising the delivery technology
- AP Pharma' s product pipeline
- Sales forecasts of products utilising the delivery technology
- Competitor Ratio Analysis
- ArmaGen Technologies
- Proprietary delivery technology
- ArmaGen' s BBB delivery technology
- Applications in the pharma industry
- Management/technical expertise
- Competition within the delivery technology sector
- Products in development/approved utilising the delivery technology
- ArmaGen Technologies' product pipeline
- Sales forecasts of products utilising the delivery technology
- Competitor Ratio Analysis
- BioDelivery Sciences International
- Proprietary delivery technology
- Bioral Technology
- Applications in the pharma industry
- Management/technical expertise
- Competition within the delivery technology sector
- Products in development/approved utilising the delivery technology
- BDSI' s product pipeline
- Sales forecasts of products utilising the delivery technology
- Competitor Ratio Analysis
- Calando Pharmaceuticals
- Proprietary delivery technology
- Schematic of cyclodextrin polymeric nanoparticles
- Applications in the pharma industry
- Management/technical expertise
- Competition within the delivery technology sector
- Products in development/approved utilising the delivery technology
- Calando' s product pipeline
- Sales forecasts of products utilising the delivery technology
- Calando' s sales forecasts
- Competitor Ratio Analysis
- Cequent Pharmaceuticals
- Proprietary delivery technology
- Application in the pharma industry
- Management/technical expertise
- Competition within the delivery technology sector
- Products in development/approved utilising the delivery technology
- Cequent' s product pipeline
- Sales forecasts of products utilising the delivery technology
- Cequent' s sales forecasts
- Competitor Ratio Analysis
- Copernicus Therapeutics
- Proprietary delivery technology
- Uptake and trafficking of condensed nanoparticle DNA
- Applications in the pharma industry
- Management/technical expertise
- Competition within the delivery technology sector
- Products in development/approved utilising the delivery technology
- Copernicus' product pipeline
- Sales forecasts of products utilising the delivery technology
- Competitor Ratio Analysis
- Diatos SA
- Proprietary delivery technology
- Applications in the pharma industry
- Management/technical expertise
- Competition within the delivery technology sector
- Products in development/approved utilising the delivery technology
- Diatos' product pipeline
- Sales forecasts of products utilising the delivery technology
- Competitor Ratio Analysis
- DOR BioPharma, Inc.
- Proprietary delivery technology
- Applications in the pharma industry
- Management/technical expertise
- Competition within the delivery technology sector
- Products in development/approved utilising the delivery technology
- DOR' s product pipeline
- Sales forecasts of products utilising the delivery technology
- Competitor Ratio Analysis
- Expression Genetics, Inc.
- Proprietary delivery technology
- TheraPlas Technology Platform
- Applications in the pharma industry
- Management/technical expertise
- Competition within the delivery technology sector
- Products in development/approved utilising the delivery technology
- EGEN' s product pipeline
- Sales forecasts of products utilising the delivery technology
- EGEN' s sales forecasts
- Competitor Ratio Analysis
- Inovio Biomedical Corporation
- Proprietary delivery technology
- Inovio' s gene delivery platform
- Applications in the pharma industry
- Management/technical expertise
- Competition within the delivery technology sector
- Products in development/approved utilising the delivery technology
- Inovio' s product pipeline
- Sales forecasts of products utilising the delivery technology
- Inovio' s sales forecasts
- Competitor Ratio Analysis
- MaxCyte, Inc.
- Proprietary delivery technology
- MaxCyte' s GT exvivo cell loading system
- Applications in the pharma industry
- Management/technical expertise
- Competition within the delivery technology sector
- Products in development/approved utilising the delivery technology
- MaxCyte' s product pipeline
- Sales forecasts of products utilising the delivery technology
- Competitor Ratio Analysis
- Nanotherapeutics
- Proprietary delivery technology
- Applications in the pharma industry
- Management/technical expertise
- Competition within the delivery technology sector
- Products in development/approved utilising the delivery technology
- Nanotherapeutics' product pipeline
- Sales forecasts of products utilising the delivery technology
- Competitor Ratio Analysis
- NeoPharm
- Proprietary delivery technology
- Management/technical expertise
- Competition within the delivery technology sector
- Products in development/approved utilising the delivery technology
- NeoPharm' s product pipeline
- Sales forecasts of products utilising the delivery technology
- Competitor Ratio Analysis
- Novagali Pharma SA
- Proprietary delivery technology
- Management/technical expertise
- Competition within the delivery technology sector
- Products in development/approved utilising the delivery technology
- Novagali' s product pipeline
- Sales forecasts of products utilising the delivery technology
- Competitor Ratio Analysis
- Oxford Biomedica
- Proprietary delivery technology
- Management/technical expertise
- Competition within the delivery technology sector
- Products in development/approved utilising the delivery technology
- Oxford Biomedica' s product pipeline
- Sales forecasts of products utilising the delivery technology
- Oxford Biomedica' s sales forecasts
- Competitor Ratio Analysis
- PCI Biotech
- Proprietary delivery technology
- PCI enhances siRNA' s gene silencing effect and improves gene delivery
- Applications in the pharma industry
- Potential applications for improving the delivery of a range of drug
types
- Management/technical expertise
- Competition within the delivery technology sector
- Products in development/approved utilising the delivery technology
- PCI' s product pipeline
- Sales forecasts of products utilising the delivery technology
- Competitor Ratio Analysis
- Silence Therapeutics plc
- Proprietary delivery technology
- Applications in the pharma industry
- Management/technical expertise
- Competition within the delivery technology sector
- Products in development/approved utilising the delivery technology
- Silence Therapeutics' product pipeline
- Sales forecasts of products utilising the delivery technology
- Silence Therapeutics' sales forecasts
- Competitor Ratio Analysis
- Targeted Genetics Corporation
- Proprietary delivery technology
- Applications in the pharma industry
- Management/technical expertise
- Competition within the delivery technology sector
- Products in development/approved utilising the delivery technology
- TGEN' s product pipeline
- Sales forecasts of products utilising the delivery technology
- Targeted Genetics sales forecasts
- Competitor Ratio Analysis
- Tekmira Pharmaceuticals Corporation
- Proprietary delivery technology
- Applications in the pharma industry
- Management/technical expertise
- Competition within the delivery technology sector
- Products in development/approved utilising the delivery technology
- Tekmira' s product pipeline
- ales forecasts of products utilising the delivery technology
- Tekmira' s sales forecasts
- Competitor Ratio Analysis
- TissueGene, Inc.
- Proprietary delivery technology
- Manufacturing TissueGene-C cell mediated gene therapies
- Applications in the pharma industry
- Application of TissueGene-C cell mediated gene therapy in orthopaedics
- Management/technical expertise
- Competition within the delivery technology sector
- Products in development/approved utilising the delivery technology
- TissueGene' s product pipeline
- Sales forecasts of products utilising the delivery technology
- Competitor Ratio Analysis
- Vical, Inc.
- Proprietary delivery technology
- Schematic of p-DNA delivery and utilisation in DNA vaccines
- Applications in the pharma industry
- Management/technical expertise
- Competition within the delivery technology sector
- Products in development/approved utilising the delivery technology
- Vical' s product pipeline
- Sales forecasts of products utilising the delivery technology
- Vical' s sales forecasts
- Competitor Ratio Analysis
- Zosano Pharma, Inc.
- Proprietary delivery technology
- ZP Patch Technology
- Applications in the pharma industry
- Management/technical expertise
- Competition within the delivery technology sector
- Products in development/approved utilising the delivery technology
- Zosano Pharma' s product pipeline
- Sales forecasts of products utilising the delivery technology
- Competitor Ratio Analysis
- APPENDIX 1
- Global nucleic acid approved drugs sales 2008-2018
- APPENDIX 2
- Global nucleic acid developmental drugs sales 2008-2018
- APPENDIX 3
- Competitor Ratio Analysis Criteria
- Key Nucleic acid delivery companies by 2018
- GLOSSARY
- ACRONYMS
- ENDNOTES
DRUG DELIVERY TECHNOLOGIES: TARGETED
- EXECUTIVE SUMMARY
- INTRODUCTION
- Overview of delivery technologies for targeted delivery: past, present &
future
- Leading technology platforms for systemic targeted drug delivery
- Systemic targeted delivery: motivators & resistors
- Motivators
- Systemic targeted delivery technology motivators
- Resistors
- Systemic targeted delivery technology resistors
- TARGETED DELIVERY TECHNOLOGIES
- Types of systemic targeted delivery platform in development in the
pharma industry
- Targeting ligands
- Antibody fragment conjugate delivery
- Antibody-directed enzyme pro-drug targeted delivery
- Peptide-induced release for targeted delivery
- Small molecule conjugate delivery
- Nucleomic mediated targeted intranuclear delivery
- Cobalamin mediated targeted intracellular delivery
- Non-biological targeting platforms
- Magnetically targeted delivery
- Photosensitive targeted delivery
- Current therapeutic applications for systemic targeted delivery
- Leading systemic targeted products in development
- Approved systemic and targeted drugs
- Future commercial applications & opportunities
- STRATEGIE S OF DRUG DELIVERY COMPANIES
- Leading targeted drug delivery companies
- Leading systemic targeted delivery specialists
- Partnerships & acquisitions
- Strategic alliances
- Strategic acquisitions
- Recent market activity in targeted delivery companies
- Intellectual Property
- Targeted drug delivery patents
- THE TARGETED DELIVERY MARKET
- Now 2009
- Approved targeted delivery product sales
- Future 2018
- Global targeted-release product sales
- Novel targeted delivery product sales
- COMPETITOR ANALYSIS
- Movers & Shakers: Cutting edge or losing their grip
- Movers & shakers in targeted drug delivery systems
- Abraxis Biosciences
- Proprietary delivery technology
- Abraxis Protosphere - nab technology
- Applications in the pharma industry
- Management/technical expertise
- Competition within the delivery technology sector
- Products in development/approved utilising the delivery technology
- Abraxis' product pipeline
- Sales forecasts of products utilising the delivery technology
- Abraxis' targeted sales forecasts
- Competitor Ratio Analysis
- Access Pharmaceuticals
- Proprietary delivery technology
- Cobalamin targeted delivery
- Schematic of targeted nanoparticle
- Targeted delivery of cancer subtypes via folate polymer, Vitamin B12
polymer and biotin polymers
- Applications in the pharma industry
- Management/technical expertise
- Competition within the delivery technology sector
- Products in development/approved utilising the delivery technology
- Access Pharmaceuticals' product pipeline
- Sales forecasts of products utilising the delivery technology
- Access Pharmaceuticals' sales forecasts
- Competitor Ratio Analysis
- ALZA Corporation
- Proprietary delivery technology
- Applications in the pharma industry
- Management/technical expertise
- Competition within the delivery technology sector
- Products in development/approved utilising the delivery technology
- ALZA' s targeted product pipeline
- Sales forecasts of products utilising the delivery technology
- ALZA' s drug delivery sales
- Competitor Ratio Analysis
- ArmaGen Technologies
- Proprietary delivery technology
- Applications in the pharma industry
- Management/technical expertise
- Competition within the delivery technology sector
- Products in development/approved utilising the delivery technology
- ArmaGen Technologies' product pipeline
- Sales forecasts of products utilising the delivery technology
- Competitor Ratio Analysis
- Avidimer Therapeutics
- Proprietary delivery technology
- Targeted avidimer for methotrexate delivery
- Applications in the pharma industry
- Management/technical expertise
- Competition within the delivery technology sector
- Products in development/approved utilising the delivery technology
- Avidimer' s product pipeline
- Sales forecasts of products utilising the delivery technology
- Competitor Ratio Analysis
- Calando Pharmaceuticals
- Proprietary delivery technology
- Schematic of Cyclosert technology
- Schematic of RONDEL technology
- Applications in the pharma industry
- Management/technical expertise
- Competition within the delivery technology sector
- Products in development/approved utilising the delivery technology
- Calando' s product pipeline
- Sales forecasts of products utilising the delivery technology
- Calando' s sales forecasts
- Competitor Ratio Analysis
- Cell Therapeutics
- Proprietary delivery technology
- CTI' s polyglutamate polymer technology
- Applications in the pharma industry
- Management/technical expertise
- Competition within the delivery technology sector
- Products in development/approved utilising the delivery technology
- CTI' s product pipeline
- Sales forecasts of products utilising the delivery technology
- CTI' s targeted drug delivery sales
- Competitor Ratio Analysis
- Cerulean Pharma Inc.
- Proprietary delivery technology
- Applications in the pharma industry
- Management/technical expertise
- Competition within the delivery technology sector
- Products in development/approved utilising the delivery technology
- Cerulean' s product pipeline
- Sales forecasts of products utilising the delivery technology
- Competitor Ratio Analysis
- Copernicus Therapeutics
- Proprietary delivery technology
- Applications in the pharma industry
- Management/technical expertise
- Competition within the delivery technology sector
- Products in development/approved utilising the delivery technology
- Copernicus' product pipeline
- Sales forecasts of products utilising the delivery technology
- Competitor Ratio Analysis
- CytImmune Sciences Inc.
- Proprietary delivery technology
- Applications in the pharma industry
- Management/technical expertise
- Competition within the delivery technology sector
- Products in development/approved utilising the delivery technology
- CytImmune' s' product pipeline
- Sales forecasts of products utilising the delivery technology
- CytImmune' s sales forecasts
- Competitor Ratio Analysis
- Diatos SA
- Proprietary delivery technology
- Applications in the pharma industry
- Management/technical expertise
- Competition within the delivery technology sector
- Products in development/approved utilising the delivery technology
- Diatos' product pipeline
- Sales forecasts of products utilising the delivery technology
- Diatos' targeted drug delivery sales
- Competitor Ratio Analysis
- Enzon Pharmaceuticals, Inc.
- Proprietary delivery technology
- Applications in the pharma industry
- Management/technical expertise
- Competition within the delivery technology sector
- Products in development/approved utilising the delivery technology
- Enzon' s product pipeline
- Sales forecasts of products utilising the delivery technology
- Enzon' s targeted product sales
- Competitor Ratio Analysis
- Endocyte Inc.
- Proprietary delivery technology
- Applications in the pharma industry
- Management/technical expertise
- Competition within the delivery technology sector
- Products in development/approved utilising the delivery technology
- Endocyte' s product pipeline
- Sales forecasts of products utilising the delivery technology
- Endocyte' s targeted drug delivery sales
- Competitor Ratio Analysis
- Eurand
- Proprietary delivery technology
- Applications in the pharma industry
- Management/technical expertise
- Competition within the delivery technology sector
- Products in development/approved utilising the delivery technology
- Eurand' s product pipeline
- Sales forecasts of products utilising the delivery technology
- Competitor Ratio Analysis
- ImmunoGen
- Proprietary delivery technology
- Applications in the pharma industry
- Management/technical expertise
- Competition within the delivery technology sector
- Products in development/approved utilising the delivery technology
- ImmunoGen' s product pipeline
- Sales forecasts of products utilising the delivery technology
- ImmunoGen' s targeted delivery sales
- Competitor Ratio Analysis
- ImaRx Therapeutics
- Proprietary delivery technology
- Applications in the pharma industry
- Management/technical expertise
- Competition within the delivery technology sector
- Products in development/approved utilising the delivery technology
- ImaRx' product pipeline
- Sales forecasts of products utilising the delivery technology
- Competitor Ratio Analysis
- NanoBioMagnetics, Inc.
- Proprietary delivery technology
- Applications in the pharma industry
- Management/technical expertise
- Competition within the delivery technology sector
- Products in development/approved utilising the delivery technology
- NanoBioMagnetics' product pipeline
- Sales forecasts of products utilising the delivery technology
- Competitor Ratio Analysis
- Nanobiotix
- Proprietary delivery technology
- Nanobiotix' NanoXray
- Applications in the pharma industry
- Management/technical expertise
- Competition within the delivery technology sector
- Products in development/approved utilising the delivery technology
- Nanobiotix' product pipeline
- Sales forecasts of products utilising the delivery technology
- Competitor Ratio Analysis
- NanoCarrier
- Proprietary delivery technology
- NanoCoat technology
- Applications in the pharma industry
- Management/technical expertise
- Competition within the delivery technology sector
- Products in development/approved utilising the delivery technology
- NanoCarrier' s product pipeline
- Sales forecasts of products utilising the delivery technology
- NanoCarrier' s targeted drug delivery sales
- Competitor Ratio Analysis
- Nano Interface Technology
- Proprietary delivery technology
- Applications in the pharma industry
- Management/technical expertise
- Competition within the delivery technology sector
- Products in development/approved utilising the delivery technology
- NITI' s product pipeline
- Sales forecasts of products utilising the delivery technology
- Competitor Ratio Analysis
- Nektar Therapeutics
- Proprietary delivery technology
- Large molecule conjugate delivery
- Small molecule conjugate delivery
- Applications in the pharma industry
- Management/technical expertise
- Competition within the delivery technology sector
- Products in development/approved utilising the delivery technology
- Nektar' s product pipeline
- Sales forecasts of products utilising the delivery technology
- Nektar' s targeted sales forecasts
- Competitor Ratio Analysis
- NeoPharm
- Proprietary delivery technology
- Management/technical expertise
- Competition within the delivery technology sector
- Products in development/approved utilising the delivery technology
- NeoPharm' s product pipeline
- Sales forecasts of products utilising the delivery technology
- NeoPharm' s targeted product pipeline
- Competitor Ratio Analysis
- Novosom AG
- Proprietary delivery technology
- Schematic of SMARTICLES mechanism of targeted delivery
- Applications in the pharma industry
- Management/technical expertise
- Competition within the delivery technology sector
- Products in development/approved utilising the delivery technology
- Novosom' s product pipeline
- Sales forecasts of products utilising the delivery technology
- Competitor Ratio Analysis
- PCI Biotech Holding ASA
- Proprietary delivery technology
- Potential applications for improving the delivery of a range of drug
types
- Applications in the pharma industry
- Management/technical expertise
- Competition within the delivery technology sector
- Products in development/approved utilising the delivery technology
- PCI' s product pipeline
- Sales forecasts of products utilising the delivery technology
- PCI' s targeted product sales
- Competitor Ratio Analysis
- Quest PharmaTech
- Proprietary delivery technology
- Applications in the pharma industry
- Management/technical expertise
- Competition within the delivery technology sector
- Products in development/approved utilising the delivery technology
- Quest PharmaTech' s product pipeline
- Sales forecasts of products utilising the delivery technology
- Quest PharmaTech' s targeted product sales
- Competitor Ratio Analysis
- Seattle Genetics
- Proprietary delivery technology
- Schematic of ADC' s
- Applications in the pharma industry
- Management/technical expertise
- Competition within the delivery technology sector
- Products in development/approved utilising the delivery technology
- Seattle Genetic' s product pipeline
- Sales forecasts of products utilising the delivery technology
- Seattle Genetic' s targeted delivery sales
- Competitor Ratio Analysis
- Spherics, Inc.
- Proprietary delivery technology
- Spherics' Oral Targeted Delivery Technologies
- Applications in the pharma industry
- Management/technical expertise
- Competition within the delivery technology sector
- Products in development/approved utilising the delivery technology
- Spheric' s product pipeline
- Sales forecasts of products utilising the delivery technology
- Spheric' s product sales
- Competitor Ratio Analysis
- Starpharma
- Proprietary delivery technology
- Starpharma' s polyvalent dendrimers
- Applications in the pharma industry
- Management/technical expertise
- Competition within the delivery technology sector
- Products in development/approved utilising the delivery technology
- Starpharma' s product pipeline
- Sales forecasts of products utilising the delivery technology
- Competitor Ratio Analysis
- Supratek Pharma Inc.
- Proprietary delivery technology
- Applications in the pharma industry
- Management/technical expertise
- Competition within the delivery technology sector
- Products in development/approved utilising the delivery technology
- Supratek' s product pipeline
- Sales forecasts of products utilising the delivery technology
- Supratek' s product sales
- Competitor Ratio Analysis
- Tekmira Pharmaceuticals Corporation
- Proprietary delivery technology
- Applications in the pharma industry
- Management/technical expertise
- Competition within the delivery technology sector
- Products in development/approved utilising the delivery technology
- Tekmira' s product pipeline
- Sales forecasts of products utilising the delivery technology
- Tekmira' s sales forecasts
- Competitor Ratio Analysis
- APPENDIX 1
- Global targeted approved drugs sales 2008-2018 (US$ millions)
- APPENDIX 2
- Global targeted developmental drugs sales 2008-2018 (US$ millions)
- APPENDIX 3
- Competitor Ratio Analysis Criteria
- Key targeted delivery companies by 2018
- GLOSSARY
- ACRONYMS
- BIBLIOGRAPHY
- ENDNOTES
